Want to see PPBT full AI Analyst Report?
Top Page
Purple Biotech
(NASDAQ:PPBT)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:Reiterated
Date:08/18/26
PPBT scores low primarily due to very weak financial performance (minimal revenue, widening losses, and ongoing negative cash flow), despite low leverage. Technicals add additional pressure given the stock’s position below key longer-term moving averages and a negative MACD. Valuation provides little support because losses make P/E uninformative and no dividend yield is available.
Positive Factors
Strengthening oncology intellectual property
The new U.S. patent allowance strengthens protection for CAPTN-3’s modular multispecific antibody architecture and may improve the company’s negotiating position with development or licensing partners. Durable intellectual-property coverage can preserve pipeline differentiation while programs advance.
Negative Factors
No meaningful commercial revenue and persistent losses
The absence of meaningful revenue leaves the company dependent on research progress, partnerships, financing, or eventual product approval to build an economic base. Persistent and widening losses also show that current R&D spending is not yet supported by a stable commercial offset.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthening oncology intellectual property
The new U.S. patent allowance strengthens protection for CAPTN-3’s modular multispecific antibody architecture and may improve the company’s negotiating position with development or licensing partners. Durable intellectual-property coverage can preserve pipeline differentiation while programs advance.
Read all positive factors
Purple Biotech (PPBT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.64M
Dividend YieldN/A
Average Volume (3M)2.66M
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS Growth-151.47%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.22
Shares Outstanding1,620,982
10 Day Avg. Volume60,167
30 Day Avg. Volume2,659,817
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.25
Price to Sales (P/S)0.00
P/FCF Ratio-5.69
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.00Price Target Upside924.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.31
Revenue Forecast (FY)N/A
Purple Biotech Business Overview & Revenue Model
Company Description
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline ...
How the Company Makes Money
Purple Biotech’s revenue model is primarily based on (1) partnering/licensing arrangements and (2) any related collaboration payments tied to its drug candidates. In such arrangements, the company may earn upfront payments for granting rights to d...
Purple Biotech Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.28M | -26.25M | -7.05M | -19.72M | -21.49M | -17.52M |
| Net Income | -24.49M | -26.39M | -7.24M | -19.88M | -21.67M | -18.38M |
Balance Sheet | ||||||
| Total Assets | 14.17M | 17.57M | 37.04M | 44.30M | 54.62M | 70.20M |
| Cash, Cash Equivalents and Short-Term Investments | 6.11M | 9.57M | 8.52M | 15.41M | 32.11M | 47.20M |
| Total Debt | 134.00K | 244.00K | 183.00K | 351.00K | 515.00K | 749.00K |
| Total Liabilities | 1.95M | 7.91M | 4.13M | 10.01M | 7.52M | 5.09M |
| Stockholders Equity | 12.27M | 9.71M | 32.86M | 34.21M | 46.91M | 64.83M |
Cash Flow | ||||||
| Free Cash Flow | -7.76M | -5.54M | -14.37M | -19.93M | -16.96M | -15.37M |
| Operating Cash Flow | -7.76M | -5.54M | -14.37M | -19.93M | -16.73M | -15.25M |
| Investing Cash Flow | 314.00K | 449.54K | 509.00K | 13.88M | 19.91M | 13.41M |
| Financing Cash Flow | 7.92M | 6.41M | 6.77M | 5.45M | 1.11M | 1.51M |
Purple Biotech Technical Analysis
Negative
1.66
Price Trends
1.56
Negative
2.05
Negative
3.75
Negative
Market Momentum
-0.05
Positive
43.49
Neutral
32.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPBT, the sentiment is Negative. The current price of 1.66 is above the 20-day moving average (MA) of 1.66, above the 50-day MA of 1.56, and below the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.49 is Neutral, neither overbought nor oversold. The STOCH value of 32.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 77 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Purple Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $3.19M | -0.56 | -232.60% | ― | -50.00% | 20.95% | |
42 Neutral | $10.64M | >-0.01 | -151.75% | ― | ― | -151.47% | |
| ― | $2.20M | -0.14 | -144.23% | ― | ― | 86.26% | |
41 Neutral | $9.20M | >-0.01 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
PPBT
Purple Biotech
1.51
-4.39
-74.39%
TCRT
Alaunos Therapeutics
1.09
-1.40
-56.22%
OGEN
Oragenics
0.49
-0.85
-63.66%
PMCB
PharmaCyte Biotech
0.44
-0.54
-55.00%
KALA
KALA BIO
0.48
-101.78
-99.54%
Purple Biotech Corporate Events
Purple Biotech Shareholders Approve All AGM Proposals, File Results with U.S. SEC
Sep 9, 2026
Purple Biotech reported that shareholders approved all proposals presented at its Annual General Meeting held on September 8, 2026, at the company’s offices in Rehovot. The resolutions, passed in accordance with Israeli Companies Law and the...
Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform
Sep 2, 2026
On September 2, 2026, Purple Biotech reported that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering precursor tri-specific antibody constructs and methods of use. The allowance expands protection ...
Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform
Aug 10, 2026
On August 10, 2026, Purple Biotech filed a Form 6-K announcing an updated corporate presentation detailing progress in its CAPTN-3 tri-specific antibody platform for solid tumors. The update highlights lead candidate IM1240, a capped CD3x5T4xNKG2A...
Purple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform
Aug 7, 2026
On August 7, 2026, Purple Biotech reported second-quarter 2026 results, highlighting progress in its CAPTN-3 T-cell engager platform and lead tri-specific antibody IM1240. As of June 30, 2026, the company held $6.1 million in cash, which managemen...
Purple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy
Jul 29, 2026
Purple Biotech Ltd. has convened its Annual General Meeting of Shareholders for September 8, 2026, at its Rehovot headquarters, inviting holders of ordinary shares and American Depositary Shares of record as of August 3, 2026. The meeting will als...
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
Jun 23, 2026
On June 23, 2026, Purple Biotech filed a Form 6-K and released an updated corporate presentation outlining its CAPTN-3 tri-specific platform and lead candidate IM1240, which is expected to enter clinical trials in 2027. The company highlighted pre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.